SCHEMBL2236618

SCHEMBL2236618

Cc1ccc(S(=O)(=O)Oc2ccc(NC(=O)NCCCl)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP1 P22413 4/20 0.59
ENPP2 Q13822 4/20 0.59
ENPP3 O14638 3/20 0.59
CA12 O43570 2/20 0.54
CA1 P00915 2/20 0.54
CA2 P00918 2/20 0.54
CA9 Q16790 2/20 0.54
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
SMN1; SMN2 Q16637 3/20 0.50
MAPT P10636 2/20 0.50
CA4 P22748 1/20 0.50
CA7 P43166 1/20 0.50
ALDH1A1 P00352 4/20 0.48
RECQL P46063 1/20 0.48
LMNA P02545 1/20 0.48
KDM4E B2RXH2 1/20 0.48
DHODH Q02127 1/20 0.47
HSP90AA1 P07900 1/20 0.47
CNR1 P21554 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2238471 1.00 ENPP1 (0.59) ENPP1ENPP2ENPP3CA12CA1
SCHEMBL2237256 0.90 SMN1; SMN2 (0.61) CA12CA1CA2CA9MEN1
SCHEMBL2235070 0.90 SMN1; SMN2 (0.61) CA12CA1CA2CA9MEN1
SCHEMBL2235718 0.89 MEN1 (0.51) ENPP1ENPP2ENPP3CA12CA1
SCHEMBL2234445 0.87 CA12 (0.56) ENPP1ENPP2ENPP3CA12CA1
SCHEMBL13826884 0.86 GPR17 (0.53) ENPP1ENPP2ENPP3SMN1; SMN2MAPT
SCHEMBL22187256 0.86 ENPP2 (0.67) ENPP1ENPP2ENPP3CA12CA1
SCHEMBL14217272 0.83 ALDH1A1 (0.47) ENPP1ENPP2ENPP3CA12CA1
SCHEMBL2239217 0.83 ALDH1A1 (0.47) ENPP1ENPP2ENPP3CA12CA1
SCHEMBL10192079 0.83 CNR1 (0.63) CA12CA1CA2CA9MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
EP-2536693-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS Université Laval (CA) 2012-12-26 EP disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
WO-2012142698-A1 ALKYLUREA DERIVATIVES ACTIVE AGAINST CANCER CELLS UNIVERSITE LAVAL (CA) 2012-10-26 WO disclosed
WO-2012142698-A1 ALKYLUREA DERIVATIVES ACTIVE AGAINST CANCER CELLS UNIVERSITE LAVAL (CA) 2012-10-26 WO disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS CCNY, RPS4Y1, TPX2 ENPP1 3542/4885ENPP2 2894/4885ENPP3 3314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.